UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

Journal of the European Academy of Dermatology and Venereology, 2015-12, Vol.29 (12), p.2277-2294

2015

Volltextzugriff (PDF)

A multicentre open‐label study of apremilast in palmoplantar pustulosis (APLANTUS)

Journal of the European Academy of Dermatology and Venereology, 2021-10, Vol.35 (10), p.2045-2050

2021

Volltextzugriff (PDF)

Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice

Journal of the European Academy of Dermatology and Venereology, 2019-04, Vol.33 (4), p.700-708

2019

Volltextzugriff (PDF)

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2014-04, Vol.28 (4), p.438-453

2014

Volltextzugriff (PDF)

Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus

Journal of the European Academy of Dermatology and Venereology, 2018-10, Vol.32 (S3), p.3-14

2018

Volltextzugriff (PDF)

Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease

Journal of the European Academy of Dermatology and Venereology, 2020-06, Vol.34 (6), p.1161-1173

2020

Volltextzugriff (PDF)

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (2), p.476-485

2021

Volltextzugriff (PDF)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

Journal of the European Academy of Dermatology and Venereology, 2017-03, Vol.31 (3), p.507-517

2017

Volltextzugriff (PDF)

European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC

Journal of the European Academy of Dermatology and Venereology, 2017-12, Vol.31 (12), p.1951-1963

2017

Volltextzugriff (PDF)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

Journal of the European Academy of Dermatology and Venereology, 2018-03, Vol.32 (3), p.397-402

2018

Volltextzugriff (PDF)

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

Journal of the European Academy of Dermatology and Venereology, 2009-10, Vol.23 (s2), p.1-70

2009

Volltextzugriff (PDF)

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

Journal of the European Academy of Dermatology and Venereology, 2017-10, Vol.31 (10), p.1686-1692

2017

Volltextzugriff (PDF)

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

Journal of the European Academy of Dermatology and Venereology, 2021-07, Vol.35 (7), p.1536-1542

2021

Volltextzugriff (PDF)

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (2), p.450-457

2021

Volltextzugriff (PDF)

Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase

Journal of the European Academy of Dermatology and Venereology, 2022-03, Vol.36 (3), p.453-461

2022

Volltextzugriff (PDF)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

Journal of the European Academy of Dermatology and Venereology, 2015-10, Vol.29 (10), p.2002-2010

2015

Volltextzugriff (PDF)

Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3

Journal of the European Academy of Dermatology and Venereology, 2022-08, Vol.36 (8), p.1275-1283

2022

Volltextzugriff (PDF)

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

Journal of the European Academy of Dermatology and Venereology, 2019-02, Vol.33 (2), p.333-339

2019

Volltextzugriff (PDF)

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

Journal of the European Academy of Dermatology and Venereology, 2022-12, Vol.36 (12), p.2393-2400

2022

Volltextzugriff (PDF)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

Journal of the European Academy of Dermatology and Venereology, 2021-05, Vol.35 (5), p.1161-1175

2021

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

Journal of the European Academy of Dermatology and Venereology, 2019-03, Vol.33 (3), p.546-552

2019

Volltextzugriff (PDF)

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3

Journal of the European Academy of Dermatology and Venereology, 2021-10, Vol.35 (10), p.2034-2044

2021

Volltextzugriff (PDF)

Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.1825-1840

2023

Volltextzugriff (PDF)

Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials

Journal of the European Academy of Dermatology and Venereology, 2023-08, Vol.37 (8), p.1634-1641

2023

Volltextzugriff (PDF)

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.919-927

2021

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

Zeitschrift / SerieJournal Of The European Academy Of Dermatology And Venereology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

Dermatology
(42)
Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Humans
(33)
Psoriasis - Drug Therapy
(24)
Severity Of Illness Index
(20)
Adult
(16)
Dermatologic Agents - Therapeutic Use
(14)
Treatment Outcome
(14)
Female
(12)
Male
(12)
Middle Aged
(12)
Double-Blind Method
(7)
Antibodies, Monoclonal, Humanized
(6)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(6)
Dermatologic Agents - Adverse Effects
(5)
Psoriasis
(5)
Quality Of Life
(5)
Aged
(4)
Antibodies, Monoclonal, Humanized - Administration & Dosage
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

A multicentre open‐label study of apremilast in palmoplantar pustulosis (APLANTUS)

Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus

Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3

Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3

Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks

Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Aktive Filter

Suchergebnisse filtern